David Sardon

Prof. Dr. David Sardon

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PDPablo Delgado-Bonet
Pablo Delgado-Bonet
BMBeatriz Davinia Tomeo Martín
Beatriz Davinia Tomeo Martín
BDBlanca Delgado-Bonet
Blanca Delgado-Bonet
DSDavid Sardon
David Sardon
ATAngel Torrado-Carvajal
Angel Torrado-Carvajal
APAna Judith Perisé-Barrios
Ana Judith Perisé-Barrios
Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient’s prognosis therefore usually worsens due to tumor progression, and adjuvant treatments are required to control the disease. Oncolytic viruses are an innovative approach that lyses the tumor cells and induces immune responses. Here, we report the intratumoral inoculation of ICOCAV15 (an oncolytic adenovirus) in a canine intracranial hemangioma, as adjuvant treatment for incomplete tumor resection. The canine patient showed no side effects, and the tumor volume decreased over the 12 months after the treatment, as measured by magnetic resonance imaging using volumetric criteria. When progressive disease was detected at month 18, a new dose of ICOCAV15 was administered. The patient died 31.9 months after the first inoculation of the oncolytic adenovirus. Furthermore, tumor-infiltrated immune cells increased in number after the viral administrations, suggesting tumor microenvironment activation. The increased number of infiltrated immune cells, the long survival time and the absence of side effects suggest that ICOCAV15 could be a safe and effective treatment and should be further explored as a novel therapy for canine hemangiomas.

15 January 2018 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Closed access
DSDavid Sardon
David Sardon
APAlberto Benito Peña
Alberto Benito Peña
ESEva Sierra
Eva Sierra
MBMarisa Andrada Borzollino
Marisa Andrada Borzollino
FFFernando Vázquez Fernández
Fernando Vázquez Fernández

10 November 2026 in Immuno
Verified
Journal Article
Open access
PDF file
Gabriella GuelfiGabriella Guelfi
Gabriella Guelfi
RVRamon Vázquez-Molinero
Ramon Vázquez-Molinero
Margherita MaranesiMargherita Maranesi
Margherita Maranesi
DSDavid Sardon
David Sardon
ERElisa Gómez Rodríguez
Elisa Gómez Rodríguez
Francesca MercatiFrancesca Mercati
Francesca Mercati
Uterine physiology may differ among cattle managed under different farming systems. This pilot study evaluated uterine NAMPT/visfatin and SPP1/osteopontin in pregnant and luteal-phase non-pregnant cattle from one intensive beef farm (INT; n = 7; nulliparous heifers aged 14–18 months, crossbred with a predominant Limousin genetic background) and one extensive farm (EXT; n = 6; Lidia cows aged 28–34 months). Formalin-fixed paraffin-embedded uterine tissues were analyzed by RT-qPCR and immunohistochemistry. Visfatin immunoreactivity was mainly localized in the luminal epithelium and uterine glands. NAMPT expression was higher in the INT cohort than in the EXT cohort (0.6331 ± 0.0855 vs. 0.3632 ± 0.0395; p = 0.0200), whereas SPP1 expression did not differ between cohorts (0.2056 ± 0.0661 vs. 0.1806 ± 0.0562; p = 0.7786). Visfatin immunostaining scores were significantly higher in INT than EXT cows in the secretory adenomeres (median [IQR]: 2.37 [2.15–2.52] vs. 1.48 [1.38–1.77]; p = 0.0012), whereas no significant difference was detected in the combined luminal epithelium/glandular duct compartment (p = 0.4639). Because age, breed, and farm of origin were confounded with management system, these findings should be interpreted as exploratory between-cohort associations.